← feed

Is NCT03187015 results overdue?

Yes — results are overdue. Primary completion was 2017-06-04; the FDAAA-801 reporting deadline (2018-06-04) passed 2939 days ago and no results are posted on ClinicalTrials.gov.

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

NCT IDNCT03187015 ↗
SponsorSyndax Pharmaceuticals (INDUSTRY)
Public issuerSyndax Pharmaceuticals Inc — SNDX (CIK 0001395937) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-06-04 (ACTUAL)
Reporting deadline2018-06-04 (completion + 365d)
Days overdue2939
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 b4c511c126b2f324… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03187015. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →